$9.29
-0.31[-3.23%]
At close: May 17
$9.29
0[0.00%]
After Hours: 4:00PM EDT
Theravance Biopharma
(NASDAQ:TBPH)Theravance Biopharma Stock (NASDAQ:TBPH), Analyst Ratings, Price Targets, Predictions
Theravance Biopharma Inc has a consensus price target of $14.88, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., BTIG, and HC Wainwright & Co. on May 14, 2024, April 12, 2024, and August 8, 2023. With an average price target of $20.33 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 118.87% upside for Theravance Biopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
SVB Leerink
Morgan Stanley
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Theravance Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | 115.29% | HC Wainwright & Co. | Douglas Tsao | → $20 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 126.05% | BTIG | Julian Harrison | → $21 | Initiates | → Buy | Get Alert |
| 08/08/2023 | Buy Now | 115.29% | HC Wainwright & Co. | Douglas Tsao | → $20 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2023 | Buy Now | 115.29% | HC Wainwright & Co. | Douglas Tsao | $19 → $20 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 104.52% | HC Wainwright & Co. | Douglas Tsao | → $19 | Reiterates | → Buy | Get Alert |
| 11/17/2022 | Buy Now | 50.7% | SVB Leerink | David Risinger | $12 → $14 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 104.52% | HC Wainwright & Co. | Douglas Tsao | $12 → $19 | Maintains | Buy | Get Alert |
| 07/25/2022 | Buy Now | 7.64% | Morgan Stanley | Vikram Purohit | $11 → $10 | Maintains | Underweight | Get Alert |
| 05/23/2022 | Buy Now | 29.17% | SVB Leerink | David Risinger | → $12 | Initiates | → Outperform | Get Alert |
| 03/02/2022 | Buy Now | 18.41% | Morgan Stanley | Vikram Purohit | $10 → $11 | Maintains | Underweight | Get Alert |
| 02/24/2022 | Buy Now | 29.17% | HC Wainwright & Co. | Douglas Tsao | $8 → $12 | Maintains | Buy | Get Alert |
| 11/05/2021 | Buy Now | 29.17% | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
| 09/16/2021 | Buy Now | 7.64% | Morgan Stanley | Vikram Purohit | — | Maintains | Underweight | Get Alert |
| 09/16/2021 | Buy Now | -13.89% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 09/16/2021 | Buy Now | 7.64% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
| 08/25/2021 | Buy Now | 50.7% | Morgan Stanley | Vikram Purohit | — | Downgrade | Overweight → Underweight | Get Alert |
| 08/24/2021 | Buy Now | 50.7% | Cowen & Co. | Marc Frahm | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/24/2021 | Buy Now | 212.16% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
| 08/24/2021 | Buy Now | 93.76% | Needham | Joseph Stringer | — | Maintains | Buy | Get Alert |
| 08/24/2021 | Buy Now | 126.05% | HC Wainwright & Co. | Douglas Tsao | — | Maintains | Buy | Get Alert |
| 08/04/2021 | Buy Now | 298.28% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
| 07/16/2021 | Buy Now | 190.64% | Morgan Stanley | Vikram Purohit | — | Maintains | Overweight | Get Alert |
| 06/28/2021 | Buy Now | 287.51% | SVB Leerink | Geoffrey Porges | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Theravance Biopharma (TBPH)?
The latest price target for Theravance Biopharma (NASDAQ: TBPH) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $20.00 expecting TBPH to rise to within 12 months (a possible 115.29% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Theravance Biopharma (TBPH)?
The latest analyst rating for Theravance Biopharma (NASDAQ: TBPH) was provided by HC Wainwright & Co., and Theravance Biopharma reiterated their buy rating.
When was the last upgrade for Theravance Biopharma (TBPH)?
The last upgrade for Theravance Biopharma Inc happened on November 5, 2021 when JP Morgan raised their price target to $12. JP Morgan previously had an underweight for Theravance Biopharma Inc.
When was the last downgrade for Theravance Biopharma (TBPH)?
The last downgrade for Theravance Biopharma Inc happened on August 25, 2021 when Morgan Stanley changed their price target from $27 to $14 for Theravance Biopharma Inc.
When is the next analyst rating going to be posted or updated for Theravance Biopharma (TBPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Theravance Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Theravance Biopharma was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Theravance Biopharma (TBPH) correct?
While ratings are subjective and will change, the latest Theravance Biopharma (TBPH) rating was a reiterated with a price target of $0.00 to $20.00. The current price Theravance Biopharma (TBPH) is trading at is $9.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.